SAVE Moms and Babies Act of 2025
SAVE Moms and Babies Act of 2025
Plain Language Summary
# SAVE Moms and Babies Act of 2025 - Summary **What the Bill Would Do** This bill would restrict how the FDA approves and regulates medications used to terminate pregnancies. It would prevent the FDA from approving any new abortion-related drugs and impose stricter rules on drugs already approved for this purpose.
Specifically, the bill would limit their use to the first 70 days of pregnancy, require that they only be given in person by a healthcare provider (not dispensed by mail or pharmacy), and mandate special certification for doctors who prescribe them. **Who It Affects** This legislation would impact pregnant women seeking medication-based abortion services, healthcare providers who offer these services, and pharmaceutical companies. It would also affect the FDA's regulatory authority over these drugs. **Current Status** The bill was introduced in the 119th Congress by Representative Robert Latta (R-OH) and is currently in committee, meaning it has not yet been debated or voted on by the full House of Representatives.
CRS Official Summary
Support And Value Expectant Moms and Babies Act of 2025 or the SAVE Moms and Babies Act of 2025This bill prohibits the Food and Drug Administration (FDA) from approving any new drug (either as a brand-name drug or a generic) intended to terminate a pregnancy and imposes additional restrictions on such drugs that are already approved.Under the bill, an already-approved drug intended to terminate a pregnancy may be dispensed to a patient only with a prescription. Furthermore, the FDA may not approve any labeling change that would authorize (1) using the drug after 70 days of gestation, or (2) dispensing the drug by any means other than in-person administration by the prescribing health care practitioner.The FDA must also impose additional restrictions on such already-approved drugs, including by (1) requiring the prescribing health care practitioner to receive a special certification, (2) prohibiting the practitioner from also acting as the dispensing pharmacist, and (3) requiring the practitioner to have the ability to provide surgical intervention to the patient.The bill also rescinds any investigational use exemption already granted to such a drug if the bill would have prohibited the FDA from granting the exemption. (Currently, the FDA may grant an exemption to certain market approval requirements if a drug is intended solely for use in safety and effectiveness investigations.)
Latest Action
Referred to the House Committee on Energy and Commerce.